



Cheshire and Wirral Partnership
NHS Foundation Trust



Bipolar Disorder at work




Dr Micheline Tremblay & Fiona Cooper

Aims and Objectives


- Recognising key symptoms of Bipolar Disorder.
- To identify why bipolar affects people in the workplace
 - Symptoms
 - Comorbidity
 - Pharmacotherapy
- To discuss ways of supporting someone in the workplace

Non Bipolar Person




Non Bipolar Person

Bipolar Person



Nicola's Journey



Mood Scale

Mania	10	Total loss of judgement, exorbitant spending, religious delusions and hallucinations.
	9	Lost touch with reality, incoherent, no sleep, paranoid and vindictive, reckless behaviour.
Hypomania	8	Inflated self-esteem, rapid thoughts and speech, counter-productive simultaneous tasks.
	7	Very productive, everything to excess (phone calls, writing, smoking, tea), charming and talkative.
Balanced Mood	6	Self-esteem good, optimistic, sociable and articulate, good decisions and get work done.
	5	Mood in balance, no symptoms of depression or mania. Life is going well and the outlook is good.
	4	Slight withdrawal from social situations, concentration less than usual, slight agitation.
Mild to Moderate Depression	3	Feelings of panic and anxiety, concentration difficult and memory poor, some comfort in routine.
	2	Slow thinking, no appetite, need to be alone, sleep excessive or difficult, everything a struggle.
Severe Depression	1	Feelings of hopelessness and guilt, thoughts of suicide, little movement, impossible to do anything.
	0	Endless suicidal thoughts, no way out, no movement, everything is bleak and it will always be like this.

Triggers

Death of a family member

Divorce

Imprisonment

Separation

Personal injury or illness

Retirement

Marriage

Birth of a child

Moving house

Falling in love

Outstanding personal achievement

Change in job

Going on holiday

Christmas

Pregnancy


Minor violation of the law

Dismissal from work

Financial difficulties


Change in leisure activities

Mood disorders (Pr Kortenber)



Bipolar disorder has a heterogenous longitudinal course

...irregularity is the rule, regular cycling the exception (Pr Kortenber)



Epidemiology: NICE

- Annual incidence 7 per 100,000
- Estimated lifetime prevalence – bipolar I
4–16 per 1000
- Peak onset between 15 and 19 years of age
- Suicide
 - bipolar I – 17% attempt suicide
 - bipolar disorder – 0.4% die annually by suicide

Epidemiology

Demographics

- **Male = Female**
 - More Depressive/Mixed/Rapid disorders in females
 - More manic episodes in males
- **Peak age of onset 15-19 years; before 30**
 - Mean age onset; 21
 - 90 % of patients develop the disorder before 50 years of age
- **Increased incidence in black and ethnic minority**
- **Increased incidence in upper class**

Problems of Misdiagnosis

- Efficacious treatment with mood stabilisers and appropriate counselling specific to bipolar disorder is delayed as a result of misdiagnosis¹
- When appropriate treatment for bipolar disorder is initiated for patients who have had several episodes of illness, treatment may be less effective²
- Inappropriate treatment with antidepressants can lead to an elevated risk of hypomania, mania, and cycling

Bipolar Depression

- Potentially misdiagnosed as unipolar
- Epidemiology
 - Early onset
 - Psychotic symptoms
 - Post partum
 - Treatment resistant unipolar
 - Hx of AD induced hypomania/mania
 - Change in the type of depressive symptoms over time
 - Seasonal pattern

– Mitchell, J Clin Psych, 2001


Other conditions could share similar characteristics

- Cyclothymia
- Personality Disorder
- Adult Attention Deficit Disorder
- Schizophrenia or Schizoaffective Disorder
- Substance misuse
- Organic brain syndrome
- Metabolic Disorders
- Iatrogenic



Frequent Co-morbid Conditions in Bipolar I Disorder

Disease and treatment are complicated by frequent psychiatric and physical comorbidities



ADHD=Attention deficit hyperactivity disorder

McIntyre, et al. Hum Psychopharmacol 2004;19(6):369-386

Course and Prognosis

- The onset is 21yrs in hospital studies and 17 yrs in community surveys. Late onset rare and may be precipitated by organicity.
- Average length mania; 6 months.
- 90% will have further episodes.
- Over 25 years average of 10 further episodes.
- Intervals gradually shorter.
- Pnx rather poor, worse rapid cycling.

For most patients bipolar disorder is chronic and recurrent

- The risk of recurrence in the 12 months after a mood episode is especially high in patients with BPD compared with other psychiatric disorders¹
 - 50% in 1 year
 - 75% at 4 years
 - Afterwards 10% per year

Proportion of YLDs, YLLs, and DALYs explained by the ten leading causes of total burden in 2010

DALYs=disability-adjusted life-years. YLDs=years lived with disability. YLLs=years of life lost.

	Proportion of total DALYs (95% UI)	Proportion of total YLDs (95% UI)	Proportion of total YLLs (95% UI)
Cardiovascular and circulatory diseases	11.9% (11.0–12.6)	2.8% (2.4–3.4)	15.9% (15.0–16.8)
Common infectious diseases; eg diarrhoea	8.1% (7.3–9.0)	1.2% (1.0–1.5)	11.2% (10.2–12.4)
Neonatal disorders	7.6% (7.0–8.2)	0.6% (0.5–0.7)	10.7% (10.0–11.4)
Cancer	7.4% (6.2–8.6)	22.9% (18.6–27.2)	0.5% (0.4–0.7)
Mental and substance use disorders	7.4% (6.2–8.6)	22.9% (18.6–27.2)	0.5% (0.4–0.7)
Musculoskeletal disorders	6.8% (5.4–8.2)	21.3% (17.7–24.9)	0.2% (0.2–0.3)
HIV/AIDS and tuberculosis	5.3% (4.8–5.7)	1.4% (1.0–1.9)	7.0% (6.4–7.5)
Other non-communicable diseases	5.1% (4.1–6.6)	11.1% (8.2–15.2)	2.4% (2.0–2.8)
Diabetes, urogenital, blood, and endocrine diseases	4.9% (4.4–5.5)	7.3% (6.1–8.7)	3.8% (3.4–4.3)
Unintentional injuries other than transport injuries	4.8% (4.4–5.3)	3.4% (2.5–4.4)	5.5% (4.9–5.9)

TREATMENT



When to start long term treatment?

NICE 2006

– BP-1

- 2 or more episodes
- after 1 manic episode involving significant risk & adverse consequences

– BP-2

- significant functional impairment
- significant risk of suicide
- frequent episodes

Lithium

Care • Well-being • Partnership





Adverse Effects

- Adverse effects at normal plasma level
 - Tremor, weight gain, thirst, polyuria, polydipsia
 - Precipitates or worsens skin problems
- Renal complications
 - Diabetes insipidus (inhibits renal action of ADH)
 - Chronic renal impairment? (reduced GFR)
- Hypothyroidism (5%)
- Toxicity
- Teratogenesis
 - Major congenital anomalies in early pregnancy
 - 4-12 % of births (cf 2-4% in untreated comparison groups)

Summary for Lithium

- Efficacy established in acute mania
 - Poorer response in:
 - mixed affective episodes
 - rapid cyclers
- Effective in maintenance of BPD (mania > depression)
- Appears anti-suicidal in BPD
- Side effects, acute and long term, are problematic
- Newly established national ***Lithium register***

Valproate

Adverse effects

- Nausea & vomiting
- Tremor
- Weight gain
- Alopecia
- Blood dyscrasias and hepatotoxicity (FBC & LFTs)
- Upward titration the norm
- Problematic in women of child bearing potential
 - Teratogenic (MCA:10.6% vs 2.8 %:., Artama et al, 2004).
 - Effect on cognitive development (Adab et al 2004)

Summary for Valproate

- Effective in acute mania
- Probably effective in maintenance
- Placebo controlled data lacking
- Effectively marketed, in US now more commonly used than lithium
- Valproate semi-sodium licensed for acute mania in UK (Depakote; Sanofi)
- Effects on new born are a major risk

Other anticonvulsivants

Carbamazepine

- Weak anti manic and prophylactic effect
- Drug interactions
 - induces metabolism of various drugs
 - e.g. OCP, antipsychotics, antidepressants, anticoagulants, steroids
- Teratogenic
- Adverse effects
 - nausea and vomiting
 - hepatotoxicity
 - drowsiness and diplopia

Lamotrigine

- Roles
 - antidepressant in bipolar depression?
 - prophylaxis of bipolar depression?
 - some evidence for effect in rapid cycling
 - not licensed in UK for use in BPD
- Side effects
 - rash (including S-J syndrome), cautious dose increase
 - ?teratogenic (cleft defects)

Antipsychotics

British National Formulary

Molecule	Acute Mania	Acute Depression	Prevent Mixed	Prevent Mania	Prevent Depression
Lithium	X	x		X	x
Valproate	X				
Quetiapine IR/ XL	X	X	X	X	X
OLZ	X			X	
Aripiprazole	X			X	
Risperidon e	X				

ECT

- **Indications**
 - Severe symptoms that have not responded to other treatment
 - Life-threatening condition
- **Diagnostic indications**
 - severe depression
 - prolonged or severe mania
 - catatonia
- **Consider potential risks and benefits**

General Principles for Management

- Treat the illness, not just the episodes
- Help the patient learn about destabilizing factors and early warning signs
- Therapeutic alliance

Physical Care

- Familiarisation with guidance for each group of psychotropic medication.
- Importance of basic health check
 - Initial; smoking/alcohol status, weight/height, BP, thyroid/LFTs/renal FTs, FBC, lipids, glucose.
 - Options; EEG/CT/MRI if organicity suspected, ECG/X-Ray/Drug screen if hx.

A day at the office...



MEMBERS SEATED: C. Shehab, J. Brackney, S. Orntstein, D. Brown, B. Lerner. STANDING: L. Dorman, D. Baker, T. Witby, B. Steenhoff, J. Oakman, J. Cartizano, C. Merlino, Dean Clower.

- Return to work
- Open discussion
- Help the employee to identify triggers
- Put in place reasonable adjustments
- Tools - mood scales / advance statement

A day at the office...The Receptionist



The triggers:

- The fire alarm goes off
- The constant ring of the telephone
- The lighting in the office
- Unclear tasks

A day at the office...The Firefighter



The triggers:

- Rotating shift patterns
- Disclosure / stigma
- Review meetings

References

Guidelines and Textbooks

- The management of bipolar disorder in adults, children and adolescents, in primary and secondary care; NICE CG38, www.nice.org.uk/cg034, July 2006.
- [Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology](#). Goodwin GM; Consensus Group of the British Association for Psychopharmacology. J Psychopharmacol. 2009 Jun;23(4):346-88. Epub 2009 Mar 27.
- [The World Federation of Societies of Biological Psychiatry \(WFSBP\) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression](#). Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, Kasper S; WFSBP Task Force On Treatment Guidelines For Bipolar Disorders. World J Biol Psychiatry. 2010 Mar;11(2):81-109.
- Textbooks;
 - Shorter Oxford Textbook of Psychiatry, 5th ed., Gelder et al, Oxford University Press, 2007, 846p.
 - Synopsis of Psychiatry, 10th ed., Kaplan BJ and Sadock VA, Lippincott Williams and Wilkins, 2007, 1470p.
 - Goodwin, F.K., Jamison, K.R. (1990). Manic-Depressive Illness. New York, Oxford University Press.
- Limitations
 - *‘Not a substitute for professional knowledge and clinical judgement’*

References

Journals

- Angst J, Sellaro R, [Historical perspectives and natural history of bipolar disorder](#). Biol Psychiatry. 2000 Sep 15;48(6):445-57.
- Hirschfeld et al. *J Clin Psychiatry* 2003;64:53–59
- Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB [The long-term natural history of the weekly symptomatic status of bipolar I disorder](#). Arch Gen Psychiatry. 2002 Jun;59(6):530-7.
- Judd LL, Akiskal HS, Schettler PJ, Coryell Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB [A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder](#). Arch Gen Psychiatry. 2003 Mar;60(3):261-9.
- Kessler et al. *Annu Rev Clin Psychol* 2007;3:137-158
- Matza et al. *J Clin Psychiatry* 2005;66(11):1432–440
- McIntyre, et al. *Hum Psychopharmacol* 2004;19(6):369-386
- Muller-Oerlinghausen et al. *Lancet* 2002;359:241–247; Waraich et al. *Can J Psychiatry* 2004;49:124–138; Kennedy et al. *Psychol Med* 2005;35:855–863;
- National Depressive and Manic-Depressive Association (NDMDA). *Hosp Community Psych* 1993;44(8):800–801
- World Health Organisation (WHO). THE GLOBAL BURDEN OF DISEASE: 2004 UPDATE *www.who.int* 2004;NA: 1-160
- The size and burden of mental disorders and other disorders of the brain in Europe 2010 Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79. doi: 10.1016/j.euroneuro.2011.07.018.
- *** Compiled with the kind assistance of Vicky Bramwell, CWP Library Service Manager



Fiona Cooper
National Development Manager

fcooper@bipolaruk.org.uk

01270 230260

www.bipolaruk.org.uk

twitter.com/bipolaruk

facebook.com/bipolaruk



Microsoft Internet Explorer provided by CWP ICT Service Desk

http://www.nice.org.uk/getinvolved/nice_fellows_and_scholars/fellows/MichelineTremblay.jsp

File Edit View Favorites Tools Help

Micheline Tremblay

NHS
National Institute for Health and Clinical Excellence

Sign In | Register

Home | News | Get involved | About NICE

Find guidance | NICE Pathways | Quality standards | Into practice | QOF

> Micheline Tremblay

Get involved

- Current NICE consultations
- Topic selection
- Join a NICE committee or working group
- Patients and public
- NICE Fellows and Scholars
 - Fellows**
 - Scholars
 - Mentors
 - Frequently asked questions
 - Stakeholder registration
 - Contact us

Micheline Tremblay

Adult Psychiatry and Honorary Lecturer for the University of Liverpool
Cheshire and Wirral Partnership NHS Foundation Trust


Dr Tremblay is Consultant in Adult General Psychiatry as part of a Community Mental Health Team providing specialist mental health services to the Northwich population in Cheshire.

She completed her specialist training in Quebec, Canada, as well as her Master's Degree in Experimental Sciences.

Over years Dr Tremblay has held various posts within her Trust including Clinical Director, Chair of the ElectroConvulsive Therapy Group and Medical Governor. This exposure to medical management and governance helped shape an interest for the effective management of disorders through the use of Integrated Care Pathways.

Dr Tremblay developed a special interest for Bipolar Disorder being involved in training and education with a variety of groups including psychiatric trainees as Honorary Lecturer for the University of Liverpool, practitioners including pharmacists and GPs, and most importantly users and carers through her work and involvement with Bipolar UK

As a Fellow of NICE, Dr Tremblay wishes to expand this interest in adapting a concept of Integrated Care Pathway in the management of Bipolar Disorder for use with the Patient Electronic Record systems. This tool is designed to provide cutting edge evidence based information at the finger tips of mental health practitioners. A collaboration with NICE will support the infusion of the latest information within the pathway and facilitate its dissemination. She is hoping to promote evidence based practice, training and education with



Done

Start | BipolarpresentationJune12 | Bipolar Disorder Masterd... | Clinical Challenges in BPD... | Inbox - Microsoft Outlook | Micheline Tremblay - ... | Google - Microsoft Intern...

Internet | 100% | 22:32

